PepVault
/ database / GLP-1 / Amylin Combo

CagriSema

Also: Cagrilintide + Semaglutide

Next-gen weekly combo — additive weight loss vs semaglutide alone.

Evidence
emerging
Legal status
research only
Half-life
~7 days (each component)
Routes
subq
View on Limitless LifeAdd to compare
What it is

CagriSema pairs Novo Nordisk's long-acting amylin analog cagrilintide with semaglutide. Phase 1b/2 trials suggest meaningfully greater weight loss than either alone.

Mechanism

Combines weekly cagrilintide (amylin analog) with weekly semaglutide for additive appetite suppression.

Outcomes it's matched to
Safety

Nausea additive between agents; long-term safety pending.

  • Pregnancy
  • Personal/family MTC
Legal context

Not approved. Investigational in Phase 3.

1:1 GUIDANCE

Have questions about this peptide?

Get free 1:1 guidance from a peptide professional before you start. They'll help you think through dosing, stacking, and whether this fits your goals.

REQUEST A CALL →
PepVault

An outcome-driven reference for modern peptides. Educational only — not medical advice, not a sales platform, not affiliated with any clinic.

Disclaimer: PepVault is an educational resource. Nothing on this site is medical advice. Many peptides discussed are research compounds and are not approved by the FDA or equivalent agencies. Always consult a qualified clinician before starting any protocol.

© 2026 PepVault